ALKM - Alkame Holdings Inc. Retains PCAOB Auditor Fruci & Associates to Complete 2020 and 2021 Audits
LAS VEGAS, April 28, 2022 (GLOBE NEWSWIRE) -- Alkame Holdings, Inc. (Pink Sheets: ALKM), is pleased to announce that it has retained Public Company Accounting Oversight Board (PCAOB) Certified firm, Fruci & Associates II PLLC, (www.fruci.com) to complete an audit of the company’s financial statements for the two-years ended December 31, 2020, and 2021.
“Upon completion of our two-year audit, the company intends to file an application to become listed on the OTCQB and intends to eventually become a fully reporting company,” stated Robert Eakle Alkame Holdings, Inc.
About Fruci & Associates II PLLC
Fruci & Associates II PLLC is based in Spokane Washington and is registered as a Public Company Accounting Oversight Board (PCAOB) Certified firm and is experienced in conducting audits of public companies.
For more information, please visit www.fruci.com
About Alkame Holdings, Inc.
Alkame Holdings, Inc. is a publicly traded diversified holding company. The Company's wholly owned subsidiaries include proprietary water technology with several unique properties, food and beverage manufacturing and co-packing, CBD /Hemp food and beverage manufacturing, and utilizes their enhanced water technology whenever applicable, along with several company owned developed and acquired consumer brands. The organization is diligently building a strong foundation through the launch and acquisition of appropriate business assets, and by pursuing multiple applications by placement into several emerging business sectors, such as consumer bottled water and RTD products, household pet products, and many other various water-based treatment solutions to both new and existing business platforms.
For more information, visit www.alkameholdingsinc.com .
Alkame Holdings, Inc. Investor Relations
Website: www.alkameholdingsinc.com
Email: info@alkameholdingsinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.